NGM313



NAME OF DRUG : NGM313

ALSO KNOWN AS : MK-3655

LABORATORY : Merck/NGMBio

STATUS AND ADVANCEMENT

Type of drug : β-Klotho/FGFR1c receptor

Clinical trials advancement : Analysing Results Phase 1

Estimated time to market : 126 months.

LABORATORY ABSTRACT ON THE DRUG

NOT PROVIDED

RECENT NEWS ON NGM313

SOME PUBLICATIONS RELATED WITH NGM313

SOME NASHBIOTECHS POINTS OF VIEW RELATED WITH NGM313


WWW.NASHBIOTECHS.COM  -  Copyright G DIVRY 2015-2016  - Contact and TERMS OF USE